DK1425404T3 - Vaccinia-MVA-E3L-mutanter og anvendelse deraf - Google Patents
Vaccinia-MVA-E3L-mutanter og anvendelse derafInfo
- Publication number
- DK1425404T3 DK1425404T3 DK02772289T DK02772289T DK1425404T3 DK 1425404 T3 DK1425404 T3 DK 1425404T3 DK 02772289 T DK02772289 T DK 02772289T DK 02772289 T DK02772289 T DK 02772289T DK 1425404 T3 DK1425404 T3 DK 1425404T3
- Authority
- DK
- Denmark
- Prior art keywords
- mva
- viruses
- mutant
- present
- mutants
- Prior art date
Links
- 206010046865 Vaccinia virus infection Diseases 0.000 title 1
- 208000007089 vaccinia Diseases 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24161—Methods of inactivation or attenuation
- C12N2710/24162—Methods of inactivation or attenuation by genetic engineering
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10144664A DE10144664B4 (de) | 2001-09-11 | 2001-09-11 | Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon |
| PCT/EP2002/010199 WO2003023040A2 (en) | 2001-09-11 | 2002-09-11 | Vaccinia virus mva-e3l-knockout-mutants and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1425404T3 true DK1425404T3 (da) | 2008-10-06 |
Family
ID=7698583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02772289T DK1425404T3 (da) | 2001-09-11 | 2002-09-11 | Vaccinia-MVA-E3L-mutanter og anvendelse deraf |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7049145B2 (da) |
| EP (1) | EP1425404B1 (da) |
| JP (1) | JP4406561B2 (da) |
| AT (1) | ATE399210T1 (da) |
| AU (1) | AU2002337083A1 (da) |
| CA (1) | CA2459754C (da) |
| DE (2) | DE10144664B4 (da) |
| DK (1) | DK1425404T3 (da) |
| WO (1) | WO2003023040A2 (da) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10143490C2 (de) * | 2001-09-05 | 2003-12-11 | Gsf Forschungszentrum Umwelt | Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen |
| US20070275010A1 (en) * | 2003-09-18 | 2007-11-29 | Mark Feinberg | Mva Vaccines |
| JP4606838B2 (ja) * | 2004-10-20 | 2011-01-05 | 富士フイルム株式会社 | 電子内視鏡装置 |
| US20090060947A1 (en) * | 2006-05-19 | 2009-03-05 | Sanofi Pasteur, Inc. | Immunological compositions |
| WO2010127115A1 (en) | 2009-04-30 | 2010-11-04 | Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) | Modified immunization vectors |
| RU2505606C2 (ru) | 2010-10-14 | 2014-01-27 | Адзиномото Ко., Инк. | Способ получения монатина |
| FR2969497B1 (fr) * | 2010-12-27 | 2013-06-28 | Ceva Sante Animale | Composition luminescente comme biomarqueur dans un oeuf aviaire, dispositif et procede correspondants. |
| JP6569209B2 (ja) * | 2014-01-07 | 2019-09-04 | ソニー株式会社 | 電気的測定用カートリッジ、並びに電気的測定装置及び電気的測定方法 |
| CN115300622A (zh) | 2015-02-25 | 2022-11-08 | 纪念斯隆-凯特琳癌症中心 | 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合 |
| EP3283088A4 (en) * | 2015-04-17 | 2018-10-24 | Memorial Sloan-Kettering Cancer Center | Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors |
| JP7034080B2 (ja) * | 2016-02-25 | 2022-03-11 | メモリアル スローン ケタリング キャンサー センター | ヒトｆｌｔ３ｌを発現する組換えｍｖａまたはｍｖａδｅ３ｌおよび固形腫瘍に対する免疫療法薬としてのそれらの使用 |
| CA3015650A1 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy |
| WO2017205674A1 (en) * | 2016-05-25 | 2017-11-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic vaccinia virus mutants and using same for cancer treatment |
| WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| WO2021260065A1 (en) | 2020-06-24 | 2021-12-30 | Consejo Superior De Investigaciones Científicas (Csic) | Mva-based vaccine against covid-19 expressing sars-cov-2 antigens |
| EP3928789A1 (en) | 2020-06-24 | 2021-12-29 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vaccine against covid-19 expressing sars-cov-2 antigens |
| EP4358999A1 (en) | 2021-06-23 | 2024-05-01 | Consejo Superior De Investigaciones Científicas | Mva-based vaccine expressing a prefusion-stabilized sars-cov-2 s protein |
| EP4108257A1 (en) | 2021-06-23 | 2022-12-28 | Consejo Superior De Investigaciones Científicas | Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein |
| EP4316514A1 (en) | 2022-08-03 | 2024-02-07 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vectors and their use as vaccine against sars-cov-2 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341245C (en) * | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US5990091A (en) * | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| US6004777A (en) | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| US6287570B1 (en) * | 1998-11-23 | 2001-09-11 | Patricia L. Foley | Vaccine against swine influenza virus |
| WO2000073487A1 (en) * | 1999-05-27 | 2000-12-07 | Arizona Board Of Regents | Novel viral vectors having enhanced effectiveness with dramatically reduced virulence |
| KR101163816B1 (ko) | 2005-09-22 | 2012-07-09 | 도쿄엘렉트론가부시키가이샤 | 플라즈마 처리 방법 및 장치 |
-
2001
- 2001-09-11 DE DE10144664A patent/DE10144664B4/de not_active Expired - Fee Related
-
2002
- 2002-09-11 WO PCT/EP2002/010199 patent/WO2003023040A2/en active IP Right Grant
- 2002-09-11 DK DK02772289T patent/DK1425404T3/da active
- 2002-09-11 AT AT02772289T patent/ATE399210T1/de active
- 2002-09-11 EP EP02772289A patent/EP1425404B1/en not_active Expired - Lifetime
- 2002-09-11 AU AU2002337083A patent/AU2002337083A1/en not_active Abandoned
- 2002-09-11 JP JP2003527104A patent/JP4406561B2/ja not_active Expired - Fee Related
- 2002-09-11 CA CA2459754A patent/CA2459754C/en not_active Expired - Fee Related
- 2002-09-11 US US10/488,987 patent/US7049145B2/en not_active Expired - Fee Related
- 2002-09-11 DE DE60227268T patent/DE60227268D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2459754C (en) | 2011-05-10 |
| AU2002337083A1 (en) | 2003-03-24 |
| US7049145B2 (en) | 2006-05-23 |
| EP1425404A2 (en) | 2004-06-09 |
| DE60227268D1 (de) | 2008-08-07 |
| JP4406561B2 (ja) | 2010-01-27 |
| DE10144664B4 (de) | 2005-06-09 |
| WO2003023040A3 (en) | 2003-11-27 |
| WO2003023040A2 (en) | 2003-03-20 |
| EP1425404B1 (en) | 2008-06-25 |
| CA2459754A1 (en) | 2003-03-20 |
| DE10144664A1 (de) | 2003-03-27 |
| US20050028226A1 (en) | 2005-02-03 |
| ATE399210T1 (de) | 2008-07-15 |
| JP2005502360A (ja) | 2005-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1425404T3 (da) | Vaccinia-MVA-E3L-mutanter og anvendelse deraf | |
| HUP9802217A2 (hu) | Rekombináns MVA-vírus és alkalmazása | |
| DK1292328T3 (da) | Kimære humant papillomvirus- (HPV) - molekyler og deres anvendelse | |
| CY1105232T1 (el) | Κυτταρικες σειρες συμπληρωματικοτητας | |
| HK1076835A1 (en) | Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter | |
| EP1554301A4 (en) | TETRAVALENT DENGUE VACCINE WITH A BLACK 30 NUCLEOTIDE DELETION IN 3'-UTR OF DENGUE TYPES 1,2,3 AND 4, OR ANTIGEN CHIMERAL DENGUE VIRUSES 1,2,3 AND 4 | |
| NO20072470L (no) | Malariaigangsetter/forsterkervaksine | |
| MXPA02006888A (es) | Flavivirus recombinantes y metodos para utilizar los mismos. | |
| UA82998C2 (ru) | Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті | |
| CY1106570T1 (el) | Σταθερες, εξασθενημενες μεταλλαγμενες μορφες ιου λυσσας και ζωντανια εμβολια αυτων | |
| IL168374A (en) | Vaccines against west nile virus | |
| UA90098C2 (en) | Promoter of vaccinia virus | |
| DK1594970T3 (da) | Fremgangsmåde til generering af rekombinant MVA | |
| CY1109244T1 (el) | Νευρολοιμογονο στελεχος του ιου δυτικου νειλου και εφαρμογες αυτου. | |
| DK0831899T3 (da) | Rekombinant koppevirus-calicivirus-præparater og anvendelser | |
| PH12020551944A1 (en) | Reverse peptide vaccine | |
| DE60040219D1 (de) | Infektiöses cdna klon des gb-virus b und dessen verwendungen | |
| ATE516045T1 (de) | Identifikation von vaccinia-virus-dominanten t- zell-epitopen | |
| DK1554383T3 (da) | Rekombinante MVA-stammer som potentieller vacciner mod P. falciparum-malaria | |
| TR200201081A2 (tr) | Zayıflatılmış rekombinant kuduz virüs mutantları ve bu mutantların canlı aşıları | |
| AR041515A1 (es) | Vacuna a dna contra el virus de papiloma humano | |
| HUP0103871A2 (hu) | Rekombináns CELO-vírus és CELO vírus DNS | |
| SE0002498D0 (sv) | Papillomavirus vaccine | |
| BR0318026A (pt) | Antìgenos recombinantes do vìrus da hepatite a, e, uso dos antìgenos | |
| MY146370A (en) | Classical swine fever tissue culture live vaccine virus, the tissue culture method of the same and classical swine fever tissue culture live vaccine comprising the same |